open access

Vol 15, No 1 (2012)
Reviews
Published online: 2012-04-24
Submitted: 2012-04-26
Accepted: 2012-04-26
Get Citation

Myocardial viability assessment in 18FDG PET/CT study (18FDG PET myocardial viability assessment)

Małgorzata Kobylecka, Joanna Mączewska, Katarzyna Fronczewska-Wieniawska, Tomasz Mazurek, Maria Teresa Płazińska, Leszek Królicki
Nucl. Med. Rev 2012;15(1):52-60.

open access

Vol 15, No 1 (2012)
Reviews
Published online: 2012-04-24
Submitted: 2012-04-26
Accepted: 2012-04-26

Abstract

Accurate identification of viable myocardium is crucial in patientqualification for medical or surgical treatment. Only personswith confirmed cardiac viability will benefit from revascularizationprocedures. It is also well known, that the amount of viablemyocardium assessed preoperatively is the best indicator oflong term cardiac event free survival after cardiac intervention.There are several diagnostic approaches used in current clinicalpractice for assessment of myocardial viability. Analysis ofwall thickness or myocardial contraction, evaluation of cardiacperfusion or metabolism can be assessed using followingmodalities: Echocardiography, Cardiac Molecular Imagingtechniques (PET, SPECT), Cardiovascular MR or CardiovascularCT. The article describes the methods and problems ofviability assessment in 18FDG PET study. PET imaging hasproved its accuracy and reproducibility for myocardial ischemiaand viability assessment. However this unique in its ability forshowing the particular substrate metabolism technique has unfortunately some disadvantages: currently achieved PETresolution is 0.4 cm. However the combined devices multislicecomputed tomography scanners with PET (PET/CT) are nowwidely used in clinical practice. This combination allows forwider morphologic assessments: coronary calcium scoring andnon-invasive coronary angiography may be added to myocardialperfusion/metabolic imaging if necessary.

Abstract

Accurate identification of viable myocardium is crucial in patientqualification for medical or surgical treatment. Only personswith confirmed cardiac viability will benefit from revascularizationprocedures. It is also well known, that the amount of viablemyocardium assessed preoperatively is the best indicator oflong term cardiac event free survival after cardiac intervention.There are several diagnostic approaches used in current clinicalpractice for assessment of myocardial viability. Analysis ofwall thickness or myocardial contraction, evaluation of cardiacperfusion or metabolism can be assessed using followingmodalities: Echocardiography, Cardiac Molecular Imagingtechniques (PET, SPECT), Cardiovascular MR or CardiovascularCT. The article describes the methods and problems ofviability assessment in 18FDG PET study. PET imaging hasproved its accuracy and reproducibility for myocardial ischemiaand viability assessment. However this unique in its ability forshowing the particular substrate metabolism technique has unfortunately some disadvantages: currently achieved PETresolution is 0.4 cm. However the combined devices multislicecomputed tomography scanners with PET (PET/CT) are nowwidely used in clinical practice. This combination allows forwider morphologic assessments: coronary calcium scoring andnon-invasive coronary angiography may be added to myocardialperfusion/metabolic imaging if necessary.
Get Citation

Keywords

cardiac viability, hibernation, perfusion, cardiac imaging, viability imaging, SPECT, MIBI-SPECT, PET, 18FDG-PET, PET/CT, perfusion/metabolic mismatch

About this article
Title

Myocardial viability assessment in 18FDG PET/CT study (18FDG PET myocardial viability assessment)

Journal

Nuclear Medicine Review

Issue

Vol 15, No 1 (2012)

Pages

52-60

Published online

2012-04-24

Bibliographic record

Nucl. Med. Rev 2012;15(1):52-60.

Keywords

cardiac viability
hibernation
perfusion
cardiac imaging
viability imaging
SPECT
MIBI-SPECT
PET
18FDG-PET
PET/CT
perfusion/metabolic mismatch

Authors

Małgorzata Kobylecka
Joanna Mączewska
Katarzyna Fronczewska-Wieniawska
Tomasz Mazurek
Maria Teresa Płazińska
Leszek Królicki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl